Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: From discovery to clinical development

Current Medicinal Chemistry

Volumn 19, Issue 7, 2012, Pages 938-944

  Ranieri, G ^a   Gadaleta Caldarola, G ^a   Goffredo, V ^a   Patruno, R ^b   Mangia, A ^a   Rizzo, A ^b   Sciorsci, R L ^b   Gadaleta, C D ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Bi aryl urea BAY 43 9006; HCC; RAS RAF signaling pathway; Sorafenib; TACE; Tyrosine kinase angiogenesis; VEGFR

Indexed keywords

CAPECITABINE; CARBOPLATIN; CD135 ANTIGEN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; INTERFERON; IODINATED POPPYSEED OIL; IRINOTECAN; OXALIPLATIN; PEMETREXED; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN RET; RAF PROTEIN; RAS PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER INHIBITION; CELL PROLIFERATION; CHEMOEMBOLIZATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPOPHOSPHATEMIA; LIVER CELL CARCINOMA; MALAISE; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TRANSARTERIAL CHEMOEMBOLIZATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 84858164702     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799320736     Document Type: Review

References (100)

1. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2000, 103(2), 211-25.
2. Zwick, E.; Bange, J.; Ullrich, A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol. Med., 2002, 8(1), 17-23. (Pubitemid 34044674)
3. Rajagopalan, H.; Bardelli, A.; Lengauer, C.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature, 2002, 418(6901), 934. (Pubitemid 34976022)
4. Györffy, B.; Schäfer, R. Biomarkers downstream of RAS: a search for robust transcriptional targets. Curr. Cancer Drug Targets, 2010, 10(8), 858-68.
5. Herrera, R.; Sebolt-Leopold, J.S. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol. Med., 2002, 8(4), S27-31. (Pubitemid 34297075)
6. Montagut, C.; Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett., 2009, 28(2), 125-34.
7. Doanes A.M.; Hegland D.D.; Sethi R.; Kovesdi I.; Bruder J.T.; Finkel T. VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem. Biophys. Res. Commun., 1999, 255(2), 545-8. (Pubitemid 29292296)
8. Mo, L.; Zheng, X.; Huang, H.Y.; Shapiro, E.; Lepor, H.; Cordon-Cardo, C.; Sun, T.T.; Wu, X.R. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J. Clin. Invest., 2007, 117(2), 314-25.
9. Shaw, R.J.; Cantley, L.C. Ras, PI(3)K and mTOR signalling controls tumor cell growth. Nature, 2006, 441(7092), 424-30. (Pubitemid 44050136)
10. Shapiro, P. Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy. Crit. Rev. Clin. Lab. Sci., 2002, 39(4-5), 285-330. (Pubitemid 35176967)
11. Kolch, W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J., 2000, 351(Pt 2), 289-305.
12. Davies, H.; Bignell, G.R.; Cox, C. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892), 949-54. (Pubitemid 34716871)
13. Harrisingh, M.C.; Lloyd, A.C. Ras/Raf/ERK signalling and NF1. Cell Cycle, 2004, 3(10), 1255-8.
14. Gedaly, R.; Angulo, P.; Hundley, J.; Daily, M.F.; Chen, C.; Koch, A.; Evers, B.M. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res., 2010, 30(12), 4951-8.
15. Whittaker, S.; Marais, R.; Zhu, A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 2010, 29(36), 4989-5005.
16. Hwang, Y.H.; Choy, J.Y.; Kim, S.; Chung, E.S.; Kim, T.; Koh, S.S.; Lee, B.; Bae, S.H.; Kim, J.; Park, Y.M. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol. Res., 2004, 29(2), 113-121. (Pubitemid 38667508)
17. Huynh, H.; Nguyen, T.T.; Chow, K.H.; Tan, P.H.; Soo, K.C.; Tran, E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)- MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol., 2003, 8, 3-19.
18. McKillop, I.H.; Schmidt, C.M.; Cahill, P.A.; Sitzmann, J.V. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology, 1997, 26(6), 1484-91. (Pubitemid 27520013)
19. Ito, Y.; Sasaki, Y.; Horimoto, M.; Wada, S.; Tanaka, Y.; Kasahara, A.; Ueki, T.; Hirano, T.; Yamamoto, H.; Fujimoto, J.; Okamoto, E.; Hayashi, N.; Hori, M. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology, 1998, 27(4), 951-8. (Pubitemid 28160479)
20. Feng, D.Y.; Zheng, H.; Tan, Y.; Cheng, R.X. Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J. Gastroenterol., 2001, 7(1), 33-6. (Pubitemid 32170895)
21. Stöckl, L.; Berting, A.; Malkowski, B.; Foerste, R.; Hofschneider, P.H.; Hildt, E. Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression. Oncogene. 2003, 122(17), 2604-10. (Pubitemid 36605608)
22. Hayashi, J.; Aoki, H.; Kajino, K.; Moriyama, M.; Arakawa, Y.; Hino, O. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology. 2000, 32(5), 958-61.
23. Calvisi, D.F.; Ladu, S.; Conner, E.A.; Seo, D.; Hsieh, J.T.; Factor, V.M.; Thorgeirsson, S.S. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J. Hepatol., 2011, 54(2), 311-9.
24. Meadows, K.N.; Bryant, P.; Pumiglia, K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J. Biol. Chem., 2001, 276(52), 49289-98.
25. Alavi, A.; Hood, J.D.; Frausto, R.; Stupack, D.G.; Cheresh, D.A. Role of Raf in vascular protection from distinct apoptotic stimuli. Science, 2003, 301(5629), 94-6. (Pubitemid 36801568)
26. Ranieri, G.; Ammendola, M.; Patruno, R.; Celano, G.; Zito, F.A.; Montemurro, S.; Rella, A.; Di Lecce, V.; Gadaleta, C.D.; Battista De Sarro, G.; Ribatti D. Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int. J. Oncol., 2009, 35(1), 115-20.
27. Patruno, R.; Arpaia, N.; Gadaleta, C.D.; Passantino, L.; Zizzo, N.; Misino A.; Lucarelli, N.M.; Catino, A.; Valerio, P.; Ribatti, D.; Ranieri, G. VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumor spontaneous model. J. Cell. Mol. Med., 2009, 13(3), 555-61.
28. Ranieri, G.; Grammatica, L.; Patruno, R.; Zito, A.F.; Valerio, P.; Iacobellis, S.; Gadaleta, C.; Gasparini, G.; Ribatti, D. A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. J. Cell. Mol. Med., 2007, 11(2), 362-8. (Pubitemid 46693334)
29. Gadaleta, C.D.; Ranieri, G. Trans-arterial chemoembolization as a therapy for liver tumors: New clinical developments and suggestions for combination with angiogenesis inhibitors. Crit. Rev. Oncol. Hematol., 2011, 80(1), 40-53.
30. Messerini, L.; Novelli, L.; Comin, C.E. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J. Clin. Pathol., 2004, 57, 867-71. (Pubitemid 39061438)
31. Huang, G.W.; Yang, L.Y.; Lu, W.Q. Effects of PI3K and p42/p44 MAPK on overexpression of vascular endothelial growth factor in hepatocellular carcinoma. World J. Gastroenterol., 2004, 10(6), 809-12.
32. Gadaleta, C.; Coviello, M.; Catino, A.; Venneri, M.T.; Stea, B.; Quaranta, M.; Mattioli, V.; Ranieri, G. Serum vascular endothelial growth factor concentrations in hepatocellular cancer patients undergoing percutaneously radiofrequency thermal ablation. J. Chemother., 2004, 16(5), 7-10. (Pubitemid 40052979)
33. Kanda, M.; Nomoto, S.; Nishikawa, Y.; Sugimoto, H.; Kanazumi, N.; Takeda, S.; Nakao, A. Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinicopathological parameters. J. Surg. Oncol., 2008, 98(3), 190-6.
34. Ranieri, G.; Gasparini, G. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy. Curr. Drug Targets Immune Endocr. Metabol. Disord., 2001, 1(3), 241-53.
35. Ranieri, G.; Patruno, R.; Ruggieri, E.; Montemurro, S.; Valerio, P.; Ribatti, D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr. Med. Chem., 2006, 13, 1845.
36. Ranieri, G.; Ruggieri, E.; Falco, G.; Zizzo, N.; Mattioli, E.; Zito, A.F.; Patruno, R.; Gasparini, G. Drug targets to pro-angiogenetic factors with special reference to primary peritoneal mesothelioma. Endocr. Metab. Immune Disord. Drug. Targets, 2006, 6(3), 271-7. (Pubitemid 44383210)
37. Rimassa, L.; Santoro, A. The present and the future landscape of treatment of advanced hepatocellular carcinoma. Dig. Liver Dis., 2010, 42(3), S273-80.
38. Greten, T.F.; Korangy, F.; Manns, M.P.; Malek, N.P. Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer, 2009, 100(1), 19-23.
39. Llovet, J.M.; Bruix, J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008, 48, 1312-27.
40. McDonald, O.B.; Chen, W.J.; Ellis, B.; Hoffman, C.; Overton, L.; Rink, M.; Smith, A.; Marshall, C.J.; Wood, E.R. A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors. Anal. Biochem., 1999, 2682, 318-29. (Pubitemid 29147147)
41. Wilhelm, S.; Chien, D.S. BAY 43-9006: preclinical data. Curr. Pharm. Des., 2002, 8, 2255-7.
42. Dumas, J. Protein kinase inhibitors from the urea class. Curr. Opin. Drug. Discov. Devel., 2002, 5(5), 718-27. (Pubitemid 36253791)
43. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R.A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug. Discov., 2006, 5(10), 835-44. (Pubitemid 44480537)
44. Smith, R.A.; Barbosa, J.; Blum, C.L.; Bobko, M.A.; Caringal, Y.V.; Dally, R.; Johnson, J.S.; Katz, M.E.; Kennure, N.; Kingery-Wood, J.; Lee, W.; Lowinger, T.B.; Lyons, J.; Marsh, V.; Rogers, D.H.; Swartz, S.; Walling, T.; Wild, H. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorg. Med. Chem. Lett., 2001, 1, 2775-8. (Pubitemid 32925314)
45. Lowinger, T.B.; Riedl, B.; Dumas, J.; Smith, R.A. Design and discovery of small molecules targeting raf- 1 kinase. Curr. Pharm. Des., 2002, 8, 2269-78. (Pubitemid 35189900)
46. Smith, R.A.; Dumas, J.; Adnane, L.; Wilhelm, S.M. Recent advances in the research and development of RAF kinase inhibitors. Curr. Top. Med. Chem., 2006, 6(11), 1071-89.
47. Adnane, L.; Trail, P.A.; Taylor, I.; Wilhelm, S.M. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol., 2006, 407, 597-612. (Pubitemid 43815979)
48. Ng. R.; Chen, E.X. Sorafenib (BAY 43-9006): review of clinical development. Curr. Clin. Pharmacol., 2006, 1(3), 223-8.
49. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L.E.; Bollag, G.; Trail, P.A. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cancer Res., 2004, 64(19), 7099-7109.
50. Carlomagno, F.; Anaganti, S.; Guida, T.; Salvatore, G.; Troncone, G.; Wilhelm, S.M.; Santoro, M. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst., 2006, 98(5), 326-34. (Pubitemid 43338212)
51. Wan, P.T.; Garnett, M.J.; Roe, S.M.; Lee, S.; Niculescu-Duvaz, D.; Good, V.M.; Jones, C.M.; Marshall, C.J.; Springer, C.J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cancer Genome Project. Cell, 2004, 116, 855-67. (Pubitemid 38410730)
52. Rini BI. Sorafenib. Expert Opin. Pharmacother., 2006, 7(4), 453-61. (Pubitemid 43379611)
53. Strumberg, D.; Clark, J.W.; Awada, A.; Moore, M.J.; Richly, H.; Hendlisz, A.; Hirte, H.W.; Eder, J.P.; Lenz, H.J.; Schwartz, B. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist, 2007, 12(4), 426-37.
54. Hotte, S.J.; Hirte, H.W. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr. Pharm. Des., 2002, 8(25), 2249-53. (Pubitemid 35189897)
55. Sparidans, R.W.; Vlaming, M.L.; Lagas, J.S.; Schinkel, A.H.; Schellens, J.H.; Beijnen, J.H. Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2009, 877, 269-76.
56. Minami, H.; Kawada, K.; Ebi, H, Kitagawa, K.; Kim, Y.I.; Araki, K.; Mukai, H.; Tahara, M.; Nakajima, H.; Nakajima, K. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci., 2008, 99(7), 1492-8. (Pubitemid 351761743)
57. Clark, J.W.; Eder, J.P.; Ryan, D.; Lathia, C.; Lenz, H.J. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res., 2005, 11(15), 5472-80.
58. Awada, A.; Hendlisz, A.; Gil, T.; Bartholomeus, S.; Mano, M.; de Valeriola, D.; Strumberg, D.; Brendel, E.; Haase, C.G.; Schwartz, B.; Piccart, M. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors. Br. J. Cancer, 2005, 92(10), 1855-61. (Pubitemid 40826133)
59. Moore, M.; Hirte, H.W.; Siu, L.; Oza, A.; Hotte, S.J.; Petrenciuc, O.; Cihon, F.; Lathia, C.; Schwartz, B.; Moore, M.; Hirte, H.W.; Siu, L. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann. Oncol., 2005, 16(10), 1688-94. (Pubitemid 41510145)
60. Strumberg, D.; Richly, H.; Hilger, R.A.; Schleucher, N.; Korfee, S.; Tewes, M.; Faghih, M.; Brendel, E.; Voliotis, D.; Haase, C.G.; Schwartz, B.; Awada, A.; Voigtmann, R.; Scheulen, M.E.; Seeber, S. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol., 2005, 23(5), 965-72. (Pubitemid 46202316)
61. Kupsch; P.; Henning, B.F.; Passarge, K.; Richly, H.; Wiesemann, K.; Hilger, R.A.; Scheulen, M.E.; Christensen, O.; Brendel, E.; Schwartz, B.; Hofstra, E.; Voigtmann, R.; Seeber, S.; Strumberg, D. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin. Colorectal Cancer, 2005, 5(3), 188-96.
62. Awada, A.; Gil, T.; Whenham, N.; Van Hamme, J.; Besse-Hammer, T.; Brendel, E.; Delesen, H.; Joosten, M.C.; Lathia, C.D.; Loembé, B.A.; Piccart-Ghebart, M.; Hendlisz, A. Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial. J. Clin. Pharmacol., 2011, [Epub ahead of print].
63. Davies, J.M.; Dhruva, N.S.; Walko, C.M.; Socinski, M.A.; Bernard, S.; Hayes, D.N.; Kim, W.Y.; Ivanova, A.; Keller, K.; Hilbun, L.R.; Chiu, M.; Dees, E.C.; Stinchcombe, T.E. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. Lung Cancer, 2011, 71(2), 151-5.
64. Siu, L.L.; Awada, A.; Takimoto, C.H.; Piccart, M.; Schwartz, B.; Giannaris, T.; Lathia, C.; Petrenciuc, O.; Moore, M.J. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin. Cancer Res., 2006, 12(1), 144-51. (Pubitemid 43166188)
65. Richly, H.; Kupsch, P.; Passage, K.; Grubert, M.; Hilger, R.A.; Voigtmann, R.; Schwartz, B.; Brendel, E.; Christensen, O.; Haase, C.G.; Strumberg, D. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int. J. Clin. Pharmacol. Ther., 2004, 42, 650-1.
66. Mross, K.; Steinbild, S.; Baas, F.; Gmehling, D.; Radtke, M.; Voliotis, D.; Brendel, E.; Christensen, O.; Unger, C. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur. J. Cancer, 2007, 43(1), 55-63. (Pubitemid 46054474)
67. Brendel, E.; Ludwig, M.; Lathia C.; Robert, C.; Ropert, S.; Soria, J.C.; Armand, J.P. Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2011, 68, 53-61.
68. Escudier, B.; Lassau, N.; Angevin, E.; Soria, J.C.; Chami, L.; Lamuraglia, M.; Zafarana, E.; Landreau, V.; Schwartz, B.; Brendel, E.; Armand, J.P.; Robert C. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin. Cancer Res., 2007, 13(6), 1801-1809. (Pubitemid 46952949)
69. Abou-Alfa, G.K.; Schwartz, L.; Ricci, S.; Amadori, D.; Santoro, A.; Figer, A.; de Greve, J.; Douillard, J.V.; Lathia, C.; Schwartz, B.; Taylor, I.; Moscovici, M.; Saltz, L.B. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol., 2006, 24, 4293-300. (Pubitemid 46630787)
70. Yau, T.; Chan, P.; Ng. K.K.; Chok, S.H.; Cheung, T.T.; Fan, S.T.; Poon, R.T. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer, 2009, 115(2), 428-36.
71. Abou-Alfa, G.K.; Amadori, D.; Santoro, A.; Figer, A.; De Greve, J.; Lathia, C.; Voliotis, D.; Anderson, S.; Moscovici, M.; Ricci, S. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest. Cancer Res., 2011, 4(2), 40-4.
72. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T.F.; Galle, P.R.; Seitz, J-F.; Borbath, I.; Haussinger, D.; Giannaris, T.B.Sc.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359, 378-90
73. Cheng, A.-L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; Xu, J.; Sun, Y.; Liang, H.; Liu, J.; Wang, J.; Tak, W.Y.; Pan, H.; Burok, K.; Zou, J.; Voliotis, D.; Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol., 2009, 10(1), 25-34.
74. Llovet, J.M.; Burroughs, A.; Bruix, J. Hepatocellular carcinoma. Lancet, 2003, 362(9399), 1907-17. (Pubitemid 37518510)
75. Bruix, J.; Sala, M.; Llovet, J.M. Chemoembolization for hepatocellular carcinoma. Gastroenterology, 2004, 127(5 Suppl 1), S179-88. (Pubitemid 39423386)
76. Li, X.; Feng, G.S.; Zheng, C.S.; Zhuo, C.K.; Liu, X. Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J. Gastroenterol., 2003, 9(11), 2445-9. (Pubitemid 37461245)
77. Wang, B.; Xu, H.; Gao, Z.Q.; Ning, H.F.; Sun, Y.Q.; Cao, G.W. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol., 2008, 49, 523-9.
78. Shim, J.H.; Park, J.W.; Kim. J.H.; An. M.; Kong, S.Y.; Nam. B.H.; Choi, J.I.; Kim, H.B.; Lee, W.J.; Kim, C.M. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci., 2008, 99(10), 2037-44.
79. Sergio, A.; Cristofori, C.; Cardin, R.; Pivetta, G.; Ragazzi, R.; Baldan, A.; Girardi, L.; Cillo, U.; Burra, P.; Giacomin, A.; Farinati, F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am. J. Gastroenterol., 2008, 103(4), 914-921. (Pubitemid 351506379)
80. Xiong, Z.P.; Yang, S.R.; Liang, Z.Y.; Xiao, E.H.; Yu, X.P.; Zhou, S.K.; Zhang, Z.S. Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int., 2004, 3(3), 386-90.
81. Li, X.; Feng, G.S.; Zheng, C.S.; Zhuo, C.K.; Liu, X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J. Gastroenterol., 2004, 10(19), 2878-82. (Pubitemid 39303010)
82. Liu, J.; Yi, J. Relationship between the changes of VEGF level and dendritic cells in peripheral blood of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. J. Huazhong. Univ. Sci. Technolog. Med. Sci., 2007, 27(1), 58-60.
83. Heinrich-Heine University, Duesseldorf. TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (SOCRATES). (ClinicalTrials.gov identifier: NCT00618384). US National Institute of Health, ClinicalTrials.gov (online). Available from: http://clinicaltrial.gov/ct2/show/NCT00618384? id=NCT00618384.
84. University of Bern. Sorafenib with TACE to Treat hepatocellular carcinoma (S-TACE). (ClinicalTrials.gov identifier: NCT00478374). US National Institute of Health, ClinicalTrials.gov (online). Available from: http://clinicaltrial. gov/ct2/show/NCT00478374?id=NCT00478374.
85. Medical University of Vienna. Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma. (ClinicalTrials.gov identifier: NCT00768937). US National Institute of Health, ClinicalTrials.gov (online). Available from: http://clinicaltrial.gov/ct2/show/NCT00768937?id=NCT00768937.
86. University of Pittsburgh. Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC. (ClinicalTrials.gov identifier: NCT00576056). US National Institute of Health, ClinicalTrials.gov (online). Available from: http://clinicaltrial.gov/ct2/show/NCT00576056?id=NCT00576056.
87. Taipei Veterans General Hospital, Taiwan. Study in Asia of the Combination of TACE With Sorafenib in HCC Patients (START). (ClinicalTrials.gov identifier: NCT00990860). US National Institute of Health, ClinicalTrials.gov (online). Available from: http://clinicaltrial.gov/ct2/show/NCT00990860?id= NCT00990860.
88. th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010, abstract TPS 178.
89. Chao, Y.; Yoon J.; Li, C.; Kim B.; Lee, R.; Chang, C.; Lee, T.; Hwang, J.; Chung Y. Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Proceedings of 2010 Gastrointestinal Cancers Symposium, abstract 211.
90. th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011, abstract 4107.
91. Cabrera, R.; Pannu, D.S.; Caridi, J.; Firpi, R.J.; Soldevila-Pico, C.; Morelli, G.; Clark, V.; Suman, A.; George jr, T.J.; Nelson, D.R. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment. Pharmacol. Ther., 2011, 34, 205-213.
92. Kudo, M.; Imanaka, K.; Chida, N.; Nakachi, K.; Tak, W.Y.; Takayama, T.; Yoon, J.H.; Hori, T.; Kumada, H.; Hayashi, N.; Kaneko, S.; Tsubouchi, H.; Suh, D.J.; Furuse, J.; Okusaka, T.; Tanaka, K.; Matsui, O.; Wada, M.; Yamaguchi, I.; Ohya, T.; Meinhardt, G.; Okita, K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur. J. Cancer, 2011 in press.
93. Pirrotta, M.T.; Bernardeschi, P.; Fiorentini, G. Targeted-therapy in advanced renal cell carcinoma. Curr. Med. Chem., 2011, 18(11), 1651-7.
94. Strebel, B.M.; Dufour, J.F. Combined approach to hepatocellular carcinoma: a new concept for nonresectable disease. Expert Rev. Anticancer Ther., 2008, 8(11), 1743-9.
95. Abou-Alfa, G.K.; Johnson, P.; Knox, J.J.; Capanu, M.; Davidenko, I.; Lacava, J.; Leung, T.; Gansukh, B.; Saltz, L.B. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA, 2010, 304(19), 2154-60.
96. Fiorentini, G. A new tool to enhance the efficacy of chemoembolization to treat primary and metastatic hepatic tumors. Expert Opin. Drug. Deliv., 2011, 8(4), 409-13.
97. Zhu, A.X. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer, 2008, 112(2), 250-9.
98. Spangenberg, H.C.; Thimme, R.; Blum, H.E. Targeted therapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol., 2009, 6(7), 423-32.
99. Kane, R.C.; Farrell, A.T.; Madabushi, R.; Booth, B.; Chattopadhyay, S.; Sridhara, R.; Justice, R.; Pazdur, R. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist, 2009, 14(1), 95-100.
100. Finn, R.S. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?. Clin. Cancer Res., 2010, 16(2), 390-397.